
器官芯片、类器官和AI建模如何终结动物试验?
2006年3月,六名健康志愿者抵达伦敦一家医院,接受实验性药物theralizumab的首剂给药。该药物此前已通过所有动物安全性测试,而受试者接受的剂量,比在猕猴(人类亲缘关系较近的灵长类动物)中发现安全剂量还小500倍。
Juliana Hilliard is Co-Founder of Parallel Bio, where she's building human immune system organoids to replace animal testing in drug development. Before founding Parallel Bio in 2021, Juliana trained in the lab in Vienna, Austria that invented the first organoid. She developed foundational organoid technologies for the brain, which she then applied as an R&D lead for Herophilus (née System1 Biosciences). The organoid platform she helped build was used to discover novel neurological disease targets, and then was acquired by Genentech in 2023. Juliana holds an MSc in molecular bioengineering from the Technical University, Dresden, and a BS from Virginia Tech.
2006年3月,六名健康志愿者抵达伦敦一家医院,接受实验性药物theralizumab的首剂给药。该药物此前已通过所有动物安全性测试,而受试者接受的剂量,比在猕猴(人类亲缘关系较近的灵长类动物)中发现安全剂量还小500倍。
In March 2006, six healthy volunteers arrived at a London hospital to receive the first dose of an experimental drug called theralizumab. It had already passed every animal safety test, a...
